• Usa, Moderna starts testing the vaccine on adolescents

  • Coronavirus, the Moderna vaccine test on adolescents is underway in the US

  • Vaccines.

    Moderna will produce 3 billion doses in 2022

  • Usa, from Thursday Pfizer vaccine also to children from 12 years old

Share

25 May 2021 Moderna's anti-Covid vaccine has also shown efficacy on adolescents: no cases of Covid-19 have been observed after the two doses of vaccine, consistent with a vaccine efficacy of 100%, and efficacy has been observed of the vaccine equal to 93% after the first dose. These are the data announced today by Moderna relating to the TeenCOVE study on adolescents. "We are motivated by the fact that mRNA has been highly effective in preventing Covid-19 in adolescents - said Stéphane Bancel, CEO of Moderna -. We will send these results to the Food and Drug Administration (the US drug authority) and to others. Regulatory Bodies in early June, asking for authorization ". 



If approved, it would vastly expand the number of doses available to middle and high school students before the start of the next school year. Pfizer got the green light for its vaccine on 12-15 year olds later this month.



The primary objective of immunogenicity of no less than that of the adult comparison group of the Phase 3 study was achieved, explains Moderna in a note. Furthermore, "no cases of COVID-19 were observed after the two doses of the vaccine" , "consistent with a vaccine efficacy of 100%". And "using the Center for Disease Control and Prevention (CDC) case definition, a 93% vaccine efficacy was observed after the first dose. No significant safety concerns were reported."   



The TeenCOVE study enrolled more than 3,700 participants between the ages of 12 and 18 in the United States. "We are motivated by the fact that mRNA-1273 has been highly effective in preventing COVID-19 in adolescents. It is particularly exciting to see that ModernaCOVID-19 vaccine can prevent Sars-Cov-2 infection," said Stéphane Bancel. Moderna's CEO - We will send these findings to the US FDA and other global regulators in early June, seeking permission. We continue to be committed to our work to help end the COVID-19 pandemic. "